Beneficial antioxidant properties of betaine against oxidative stress mediated by levodopa/benserazide in the brain of rats

Journal of Physiological Sciences

Volumn 65, Issue 3, 2015, Pages 243-252

  Alirezaei, Masoud ^a   Khoshdel, Zeynab ^b   Dezfoulian, Omid ^a   Rashidipour, Marzyeh ^c   Taghadosi, Vahideh ^d  

^a LORESTAN UNIVERSITY   (Iran)

^b LORESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

^d SHIRAZ UNIVERSITY   (Iran)

Author keywords

Benserazide; Betaine; Brain; Homocysteine; Levodopa; Parkinson s

Indexed keywords

ANTIOXIDANT; BENSERAZIDE; BENSERAZIDE, LEVODOPA DRUG COMBINATION; BETAINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG COMBINATION; GLUTATHIONE; GLUTATHIONE PEROXIDASE; LEVODOPA; SUPEROXIDE DISMUTASE;

ANIMAL; BRAIN; CHEMICALLY INDUCED; DRUG COMBINATION; DRUG EFFECTS; HUMAN; HYPERHOMOCYSTEINEMIA; LIPID PEROXIDATION; MALE; METABOLISM; OXIDATIVE STRESS; PARKINSON DISEASE; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIOXIDANTS; BENSERAZIDE; BETAINE; BRAIN; DOPAMINE; DOPAMINE AGENTS; DRUG COMBINATIONS; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HUMANS; HYPERHOMOCYSTEINEMIA; LEVODOPA; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE;

EID: 84939993002     PISSN: 18806546     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12576-015-0360-0     Document Type: Article

References (56)

1. Rezaei M, Alirezaei M (2014) Protective effects of Althaea officinal is L. extract in 6-hydroxydopamine-induced hemi-parkinsonism model: behavioral, biochemical and histochemical evidences. J Physiol Sci 64:171–176
2. Fahn S (1997) Levodopa-induced neurotoxicity. Does it represent a problem for the treatment of Parkinson’s disease? CNS Drugs 8:376–393
3. Shulman LM (2000) Levodopa toxicity in Parkinson disease: reality or myth? Reality—practice patterns should change. Arch Neurol 57:406–407
4. Weiner WJ (2000) Is levodopa toxic? Arch Neurol 57:408–410
5. Graham DG (1978) Oxidative pathways for catecholamines in the enesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14:633–643
6. Tse DC, McCreery RL, Adams RN (1976) Potential oxidative pathways of brain catecholamines. J Med Chem 19:37–40
7. Jenner P (2003) Oxidative stress in Parkinson’s disease. Ann Neurol 53(3):S26–S38
8. Subbarao KV, Richardson JS, Ang LC (1990) Autopsy samples of Alzheimer’s cortex show increased peroxidation in vitro. J Neurochem 55:342–345
9. Youdim MB, Ben Shachar D, Riederer P (1989) Is Parkinson’s disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand Suppl 126:47–54
10. Dal-Pizzol F, Ritter C, Cassol-Jr OJ, Rezin GT, Petronilho F, Zugno AI, Quevedo J, Streck EL (2010) Oxidative mechanisms of brain dysfunction during sepsis. Neurochir Res 35:1–12
11. Alirezaei M, Jelodar G, Niknam P, Ghayemi Z, Nazifi S (2011) Betaine prevents ethanol-induced oxidative stress and reduces total homocysteine in the rat cerebellum. J Physiol Biochem 67:605–612
12. Lee ES, Chen H, Soliman KF, Charlton CG (2005) Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology 26:361–371
13. Lutz Ulrich C (2008) Alterations in homocysteine metabolism among alcohol dependent patients-clinical, pathobiochemical and genetic aspects. Current Drug Abuse Rev 1:47–55
14. Chern CL, Huang RF, Chen YH, Cheng JT, Liu TZ (2001) Folate deficiency-induced oxidative stress and apoptosis are mediated via homocysteine-dependent overproduction of hydrogen peroxide and enhanced activation of NF-kappa B in human Hep G2 cells. Biomed Pharmacother 55:434–442
15. Ho PI, Ortiz D, Rogers E, Shea TB (2002) Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res 70:694–702
16. Bleich S, Degner D, Sperling W, Bönsch D, Thürauf N, Kornhuber J (2004) Homocysteine as a neurotoxin in chronic alcoholism. Prog Neuropsychopharmacol Biol Psychiat 28:453–464
17. Huang RF, Huang SM, Lin BS, Wei JS, Liu TZ (2001) Homocysteine thiolactone induces apoptotic DNA damage mediated by increased intracellular hydrogen peroxide and caspase 3 activation in HL-60 cells. Life Sci 68:2799–2811
18. Blundell G, Jones BG, Rose FA, Tudball N (1996) Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis 122:163–172
19. Seshadri S, Beiser A, Selhub J (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 346:476–483
20. Morris MS (2003) Homocysteine and Alzheimer’s disease. Lancet Neurol 2:425–428
21. Nissinen E, Nissinen H, Larjonmaa H, Vaananen A, Helkamaa T, Reenila I, Rauhala P (2005) The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats. J Neural Transm 112:1213–1221
22. Muller T, Jugel C, Ehret R, Ebersbach G, Bengel G, Muhlack S, Klostermann F (2011) Elevation of total homocysteine levels in patients with Parkinson´s disease treated with duodenal levodopa/carbidopa gel. J Neural Transm 118:1329–1333
23. Muller T, Renger K, Kuhn W (2004) Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch Neurol 61:657–660
24. Schapira AHV (2008) The clinical relevance of levodopa toxicity in the treatment of Parkinson’s disease. Mov Disord 23:S515–S520
25. Muller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Goetze O, Woitalla D (2006) Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease. J Neural Transm 113:1441–1448
26. Alirezaei M, Jelodar G, Ghayemi Z (2012) Antioxidant defense of betaine against oxidative stress induced by ethanol in the rat testes. Int J Pept Res Ther 18:239–247
27. Alirezaei M, Niknam P, Jelodar G (2012) Betaine elevates ovarian antioxidant enzyme activities and demonstrates methyl donor effect in non-pregnant rats. Int J Pept Res Ther 18:281–290
28. Alirezaei M, Saeb M, Javidnia K, Nazifi S, Saeb S (2012) Hyperhomocysteinemia reduction in ethanol-fed rabbits by oral betaine. Comp Clin Pathol 21:421–427
29. Craig SA (2004) Betaine in human nutrition. Am J Clin Nutr 80:539–549
30. Finkelstein JD, Martin JJ (1986) Methionine metabolism in mammals. Adaptation to methionine excess. J Biol Chem 261:1582–1587
31. Finkelstein JD, Martin JJ, Harris BJ, Kyle WE (1983) Regulation of hepatic betaine–homocysteine methyltransferase by dietary betaine. J Nutr 113:519
32. Sachdev PS, Valenzuela M, Brodaty H, Wang XL, Looi J, Lorentz L, Howard L, Jones M, Zagami AS, Gillies D, Wilcken DEL (2003) Homocysteine as a risk factor for cognitive impairment in stroke patients. Dement Geriatr Cogn Disord 15:155–162
33. Haubrich DR, Gerber NH (1981) Choline dehydrogenase. Assay, properties and inhibitors. Biochem Pharmacol 30:2993
34. Alirezaei M, Jelodar G, Ghayemi Z, Khordad Mehr M (2014) Antioxidant and methyl donor effects of betaine versus ethanol-induced oxidative stress in the rat liver. Comp Clin Pathol 23:161–168
35. Muzzi C, Bertocci E, Terzuoli L, Porcelli B, Ciari I, Pagani R, Guerranti R (2008) Simultaneous determination of serum concentrations of levodopa, dopamine, 3-O-methyldopa and á-methyldopa by HPLC. Biomed Pharmacotherap 62:253–258
36. Golbahar J, Aminzadeh MA, Hamidi SA, Omrani GR (2005) Association of red blood cell 5-methyltetrahydrfoate folate with bone mineral density in postmenopausal Iranian women. Osteop Int 16:1894–1898
37. Karthikeyan G, Thachil A, Sharma S, Kalaivani M, Ramakrishnan L (2007) Elevated high sensitivity CRP levels in patients with mitral stenosis and left atrial thrombus. Int J Cardiol 122:252–254
38. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
39. Sedlak J, Lindsay RH (1968) Estimation of total, proteinbound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 25:192–205
40. Neamati S, Alirezaei M, Kheradmand A (2011) Ghrelin acts as an antioxidant agent in the rat kidney. Int J Pept Res Ther 17:239–245
41. Claiborne A (1986) Catalase activity. In: Greenwald RA (ed) CRC handbook of methods for oxygen radical research, vol 1. CRC, Boca Raton, pp 283–284
42. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R (2003) Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 60:59–64
43. Benson R, Crowell B Jr, Hill B, Doonquah K, Charlton C (1993) The effects of L-Dopa on the activity of methionine adenosyltransferase: relevance to L-Dopa therapy and tolerance. Neurochem Res 18:325–330
44. Blandini F, Fancellu R, Martignoni E, Mangiagalli A, Pacchetti C, Samuele A, Nappi G (2001) Plasma homocysteine and L-DOPA metabolism in patients with Parkinson disease. Clin Chem 47:1102–1104
45. Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA (1997) Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 20:55–66
46. Liu XX, Wilson K, Charlton CG (2000) Effects of L-DOPA treatment on methylation in mouse brain: implications for the side effects of L-DOPA. Life Sci 66:2277–2288
47. Ossig C, Reichmann H (2013) Treatment of Parkinson’s disease in the advanced stage. J Neural Transm 120:523–529
48. De La Cruz JP, Pavı´a J, Gonza´lez-Correa JA (2000) Effects of chronic administration of S-adenosyl-l-methionine on brain oxidative stress in rats. Naunyn Schmiedebergs Arch Pharmacol 361:47–52
49. Kanbak G, Arslan OC, Dokumacioglu A, Kartkaya K, Inal ME (2008) Effects of chronic ethanol consumption on brain synaptosomes and protective role of betaine. Neurochem Res 33:539–544
50. Zhao WQ, Williams Z, Shepherd KR (2002) S-adenosyl-methionine-induced apoptosis in PC12 cells. J Neurosci Res 69:519–529
51. Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51:745–752
52. Ganesan B, Buddhan S, Anandan R, Sivakumar R, Anbinezhilan R (2010) Antioxidant defense of betaine against isoprenaline-induced myocardial infarction in rats. Mole Biol Rep 37:1319–1327
53. Kharbanda KK, Mailliard ME, Baldwin CR, Beckenhauer HC, Sorrell MF, Tuma DJ (2007) Betaine attenuates alcoholic steatosis by restoring phosphatidylcholine generation via the phosphatidylethanolamine methyltransferase pathway. J Hepatol 46:314–321
54. Vajragupta O, Boonyarat C, Murakami Y (2006) A novel neuroprotective agent with antioxidant and nitric oxide synthase inhibitory action. Free Radic Res 40:685–695
55. Wang ZJ, Liang CL, Li GM (2006) Neuroprotective effects of arachidonic acid against oxidative stress on rat hippocampal slices. Chem Biol Interact 163:207–217
56. Amiraslani B, Sabouni F, Abbasi Sh, Nazem H, Sabet M (2012) Recognition of betaine as an inhibitor of lipopolysaccharide-induced nitric oxide production in activated microglial cells. Iran Biomed J 16(2):84–89